Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients

TY - JOUR

T1 - Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients

AU - Ciofu, Oana

AU - Tolker-Nielsen, Tim

AU - Jensen, Peter Østrup

AU - Wang, Hengzhuang

AU - Høiby, Niels

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Lung infection is the main cause of morbidity and mortality in patients with cystic fibrosis and is mainly dominated by Pseudomonas aeruginosa. The biofilm mode of growth makes eradication of the infection impossible, and it causes a chronic inflammation in the airways. The general mechanisms of biofilm formation and antimicrobial tolerance and resistance are reviewed. Potential anti-biofilm therapeutic targets such as weakening of biofilms by quorum-sensing inhibitors or antibiotic killing guided by pharmacokinetics and pharmacodynamics of antibiotics are presented. The vicious circle of adaptive evolution of the persisting bacteria imposes important therapeutic challenges and requires development of new drug delivery systems able to reach the different niches occupied by the bacteria in the lung of cystic fibrosis patients.

AB - Lung infection is the main cause of morbidity and mortality in patients with cystic fibrosis and is mainly dominated by Pseudomonas aeruginosa. The biofilm mode of growth makes eradication of the infection impossible, and it causes a chronic inflammation in the airways. The general mechanisms of biofilm formation and antimicrobial tolerance and resistance are reviewed. Potential anti-biofilm therapeutic targets such as weakening of biofilms by quorum-sensing inhibitors or antibiotic killing guided by pharmacokinetics and pharmacodynamics of antibiotics are presented. The vicious circle of adaptive evolution of the persisting bacteria imposes important therapeutic challenges and requires development of new drug delivery systems able to reach the different niches occupied by the bacteria in the lung of cystic fibrosis patients.

U2 - 10.1016/j.addr.2014.11.017

DO - 10.1016/j.addr.2014.11.017

M3 - Review

C2 - 25477303

SN - 0169-409X

VL - 85

SP - 7

EP - 23

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

ER -